The U.S. FDA has approved Autolus Therapeutics’ Aucatzyl (obecabtagene autoleucel), a CD19-directed genetically modified autologous T cell immunotherapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Approval was based on results from the FELIX study, an open-label, multicenter, single-arm trial